2010-12-08B HMC21 Supporting Documents
Document Full Title Earl Baldwin of Bewley, Observations on the report Evidence Check 2: Baldwin Critique.pdf Homeopathy by the House of Commons Science and Technology Committee, February 2010 (2010). Paolo Bellavite and Andrea Signorini, The Emerging Science of Bellavite p45.pdf Homeopathy: Complexity, biodynamics, and nanopharmacology (Berkley: North Atlantic Books, 2002), p. 45. BHA Critique 0.rtf BHA Critique 1.rtf BHA Critique 2.rtf BHA comments at <http://www.britishhomeopathic.org/wp- BHA Critique 3.rtf content/uploads/2013/08/ST-parts-1-6.pdf>. BHA Critique 4.rtf BHA Critique 5.rtf BHA Critique 6.rtf ‘How much do we know?’, BMJ Clinical Evidence at BMJ Evidence 2008.webarchive <http://clinicalevidence.bmj.com/ceweb/about/knowledge.jsp>, accessed 18 May 2008. ‘How much do we know?’, BMJ Clinical Evidence at BMJ Evidence 2010.webarchive <http://clinicalevidence.bmj.com/ceweb/about/knowledge.jsp>, accessed 3 May 2010. BNF Digitalis 1.webarchive British National Formulary, § 2.1.1 ‘Cardiac glycosides’. BNF Digitalis 2.webarchive British National Formulary, § 2.1.1 ‘Cardiac glycosides’; ‘Digoxin’. British National Formulary, § 12.2.2 ‘Topical nasal decongestants’; BNF Rebound 01.webarchive ‘Sympathomimetics’; ‘Ephedrine Hydrochloride’. British National Formulary, § 10.2.2 ‘Skeletal muscle relaxants’; BNF Rebound 02.webarchive ‘Tizanidine’. British National Formulary, § 4.8.1 ‘Control of epilepsy’; ‘Phenobarbital BNF Rebound 03.webarchive and other barbiturates’. British National Formulary, § 4.10 ‘Drugs used in substance BNF Rebound 04.webarchive dependence’; ‘Opioid dependence’; ‘Lofexidine Hydrochloride’. BNF Rebound 05.webarchive British National Formulary, § 4.1.1 ‘Hypnotics’; ‘Sodium Oxybate’. BNF Rebound 06.webarchive British National Formulary, § 12.2.2 ‘Topical nasal decongestants’.
[Show full text]